<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Yangzheng Xiaoji is a traditional Chinese medical formulation that has been shown to have anticancer actions in patients with various <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The mechanisms of the potential anticancer action of Yangzheng Xiaoji are unknown </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we investigated the direct effects of Yangzheng Xiaoji on a range of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines and investigated the possible mechanism(s) of its action </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: Extract of Yangzheng Xiaoji (DME25) was prepared using <z:chebi fb="0" ids="28262">dimethyl sulfoxide</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The influence of DME25 on in vitro growth, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and migration was examined using in vitro function assays </plain></SENT>
<SENT sid="5" pm="."><plain>The effects on signalling protein kinases were assessed using western blotting </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: DME25 suppressed <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and migration of various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell, including those of breast, prostate, lung, <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Further investigation showed an involvement of the phosphatidylinositol 3-kinases/protein kinase B (PI3K/AKT) pathway in the inhibitory effect on the <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells by DME25 </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Yangzheng Xiaoji exerts its anticancer effects not only via synergistically working together with chemotherapy, but also by directly inhibiting <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and migration of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="9" pm="."><plain>The PI3K/AKT pathway is a potential signalling pathway targeted by Yangzheng Xiaoji </plain></SENT>
</text></document>